Market Doubts on Dollar Are Chance for EU, ESM Chief Says
Save
Subscribe to Economics Daily for the latest news and analysis.
A top European Union policymaker said the region should take advantage of investor doubts in the dollar and US Treasuries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Databricks valued at over $100 billion in latest fundraising amid AI rush
(Reuters) -Databricks said on Tuesday it was raising new funds that would value the data analytics firm at more than $100 billion, less than a year after its previous round, as investor appetite for artificial intelligence companies remains strong. The company expects to use the funds for AI acquisitions, as corporations and governments worldwide rush to leverage efficiencies from the nascent but rapidly evolving technology. Databricks' previous fundraising valued it at $62 billion.
Forbes
26 minutes ago
- Forbes
Figma Stock Downside To $40
The interface design software firm Figma (NYSE:FIG) had an impressive public debut last month, with its shares climbing from the $33 IPO price on the first day to approximately $80 per share at present, resulting in a market capitalization of around $40 billion. Investors have been eager to pay a premium for the company's rapid growth, impressive retention rates, and product-led adoption tactics. However, at the current price levels, there is a limited margin for error. With high growth expectations, any slowdown could expose the stock to a significant re-rating. We consider a scenario with more conservative assumptions that might cause Figma's stock to decrease by 50% to levels nearing $40 a share. Valuation Leaves No Room For Error Currently, Figma is trading at nearly 37 times the estimated revenue for 2025. This high multiple is somewhat justified by Figma's robust growth and the potential for substantial margins. Revenues jumped from less than $100 million in 2021 to $749 million in 2024. In the March quarter, Figma reported $228.2 million in revenue, marking a 46% year-over-year increase, placing it on a $913 million annualized run rate. The company also has the potential for high margins due to its well-balanced cost structure, which contrasts with many other emerging SaaS providers that excessively spend on sales and marketing. But what happens if growth slows? If revenues grow at an average annual rate of approximately 15% from fiscal year 2025 to fiscal year 2028, sales would only reach around $1.6 billion. By applying a more conservative 14 times sales multiple – still high compared to mature competitors such as Adobe at 7.5 times forward sales, Microsoft at 12.5 times, or even Snowflake at 12 times despite quicker growth – Figma's market cap would be closer to $22 billion. This translates to approximately $44 per share, which is about half of the current price. We also present a counter-scenario detailing how Figma stock can double to $160. In fact, we believe that this wide range of potential upside and downside illustrates a simple truth: Figma is a volatile stock. How Growth May Falter The likelihood of this outcome is quite plausible – competition, customer fatigue, and limited market penetration beyond core design teams could all work together to slow growth to mid-teen percentages. While Figma is favored by designers and exhibits strong customer retention, its leading position is not guaranteed. Microsoft (NASDAQ:MSFT) is integrating design and whiteboarding tools into its widely used Office 365 suite, potentially attracting enterprise users who prefer integration over specialization. See Microsoft's revenue breakdown. The smaller competitor Canva is expanding its offerings, while AI-driven tools from startups and model developers like OpenAI might fundamentally alter workflows and lessen the dependency on conventional design platforms. Should competitive pressures increase, Figma's product-led growth could stagnate. Here's a closer inspection of Key risks for Figma stock. Additionally, Figma's long-term bullish outlook relies on expanding its market beyond its original designer base to include software developers, marketers, and cross-functional teams. This presents a significantly more challenging task than merely winning over design teams. Without significant progress in these adjacent markets, Figma risks becoming stagnant in a niche, which could hinder its ability to warrant valuations seen with tech giants. Enterprise adoption is also still in nascent stages, with just over 1,000 clients paying $100,000 or more annually. If Figma fails to grow its high-value enterprise presence, both revenue growth and margin expansion may fall short of expectations. Another emerging risk is supply. Figma's IPO only released a small percentage of shares, with approximately two-thirds still owned by insiders under a lockup agreement. Once this expires in early 2026, insiders will be able to sell their shares. If growth slows down, more insiders might choose to sell, putting additional pressure on the stock. Figma possesses all the characteristics of a high-quality SaaS business – such as a sticky product, robust gross margins, and strong net dollar retention. However, trading at almost 37 times sales, investors appear to be factoring in years of rapid and flawless execution. For investors, this situation renders the stock a high-risk bet, where even minor disappointments could lead to a substantial correction. As an alternative, the Trefis Reinforced Value (RV) Portfolio has outperformed its all-cap stock benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices), delivering strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks has provided a responsive way to capitalize on favorable market conditions while minimizing losses when markets decline, as detailed in RV Portfolio performance metrics.
Yahoo
33 minutes ago
- Yahoo
Corbion and Kuehnle AgroSystems join forces to develop natural Astaxanthin from algae fermentation
Corbion, the Amsterdam-based global leader in sustainable ingredients, and US-based biotech company Kuehnle AgroSystems (KAS) have entered into a strategic partnership to develop and commercialize a high-quality, natural astaxanthin derived from non-GMO heterotrophic algae. Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms, including microalgae, salmon, and shrimp. It is widely recognized both for its human health benefits and as a key feed ingredient for salmon and other aquaculture most commercially available astaxanthin is either chemically synthesized for aquaculture use or derived from the phototrophic microalgae Haematococcus for human health applications. Corbion and KAS aim to provide a natural, algae-derived alternative produced through controlled fermentation of non-GMO, heterotrophic Haematococcus, the primary natural source of astaxanthin. The partnership will focus on developing an esterified form of astaxanthin, rich in the most bioavailable isomer, delivering superior antioxidant performance, enhanced stability, and fat solubility. Designed for both the human and animal nutrition markets, the product is particularly well-suited for nutraceuticals and aquaculture applications. By combining KAS's advanced fermentation platform and proprietary non-GMO algae strains with Corbion's industrial production capabilities, regulatory and go-to-market expertise, the two companies aim to bring this innovation to market at scale. 'This partnership reinforces our commitment to sustainable, science-based solutions,' said Robert Jan de Voogd, General Manager, Algae Ingredients North America at Corbion. 'KAS' technology offers a strong foundation to deliver high-quality natural astaxanthin to customers looking for a clean-label alternative.' 'We're proud to collaborate with Corbion to scale our technology and make premium algae-derived antioxidants more accessible worldwide' said Claude Kaplan, CEO of KAS. Development and technical transfer have already begun, with further updates to follow as the project progresses. For more information, please contact: Press: Robert Jan de Voogd, General Manager, Algae Ingredients North America+1 913 608 6764 Analysts and investors:Alex Sokolowski, Head of Investor Relations+31(0)6 46941365 About Corbion Corbion is a sustainable ingredients company dedicated to preserving what matters, including food and food production, health, and the planet. We specialize in lactic acid, lactic acid derivatives, food preservation solutions, functional blends, and algae ingredients, using our deep application and product knowledge to propel nature's ingenuity through science. With more than a century of experience, we continue working side-by-side with our customers to make our cutting-edge technologies work for them. Leveraging our advanced capabilities in fermentation and preservation technology, we help customers differentiate their products in diverse markets ranging from food and animal nutrition to home & personal care, pharmaceuticals, electronics, medical devices, and bioplastics. In 2024, Corbion generated annual sales of € 1,332.0 million with a workforce of 2,399 FTEs. Corbion is listed on Euronext Amsterdam. For more information: About KASKuehnle AgroSystems (KAS), a biotechnology company based in Hawaii, is leading the way in sustainable innovation with its development of algae-derived natural products. Leveraging its patented 'dark fermentation' process and proprietary non-GMO microalgal strains, KAS is successfully pioneering the production of natural astaxanthin — a powerful antioxidant prized in human nutrition and a vital component in aquafeed. With a commitment to sustainability, affordability, and scientific excellence, KAS's breakthrough fermentation technology offers a reliable and scalable alternative to traditional astaxanthin sources, opening new frontiers in both health and aquaculture sectors. For more information: Attachment Corbion and KAS partnership 2025Sign in to access your portfolio
